Pharmaceutical drug development: high drug prices and the hidden role of public funding
- 22 June 2020
- journal article
- review article
- Published by Springer Nature in Biologia Futura
- Vol. 72 (2) , 129-138
Abstract
In 2019, the record for the most expensive drug was broken at US$2.1 million per patient. The high costs of new drugs are justified by the pharmaceutical industry as the expense required for maintaining research and development (R&D) pipelines. However, this does not take into account that globally the public pays for between one to two-thirds of upfront R&D costs through taxpayers or charitable donations. Governments are effectively paying twice for medicines; first through R&D, and then paying the high prices upon approval. High drug prices distort research priorities, emphasising financial gains and not health gains. In this manuscript, issues surrounding the current patent-based drug development model, public funding of research and pharmaceutical lobbying will be addressed. Finally, innovations in drug development to improve public health needs and guaranteeing medication access to patients will be explored.Keywords
This publication has 42 references indexed in Scilit:
- Access to cancer medications in low- and middle-income countriesNature Reviews Clinical Oncology, 2013
- Drug versus vaccine investment: a modelled comparison of economic incentivesCost Effectiveness and Resource Allocation, 2013
- Government use licenses in Thailand: The power of evidence, civil movement and political leadershipGlobalization and Health, 2011
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- Poverty and Access to Health Care in Developing CountriesAnnals of the New York Academy of Sciences, 2008
- Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st CenturyTechnology Analysis & Strategic Management, 2007
- Clearing a Path through the Patent ThicketCell, 2006
- Investing in Prevention: What Incentive Does the Pharmaceutical Industry Have?JNCI: Journal of the National Cancer Institute, 2002
- Initial sequencing and analysis of the human genomeNature, 2001
- Pharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)The Journal of Steroid Biochemistry and Molecular Biology, 1994